UCSF Helen Diller Family Comprehensive Cancer Center
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, brain disorder, bronchial neoplasm, bronchogenic carcinoma, cancer, central nervous system cancer, central nervous system disorder, differentiated thyroid carcinoma, endocrine system disorder, epithelial neoplasm, glioma, low grade glioma, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant glioma, melanocytic neoplasm, melanoma, neoplasm, nervous system disorder, neuroendocrine neoplasm, neuroepithelial neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, thyroid gland disorder, thyroid tumor | Active, not recruiting | Phase 1 | 2026-09-01 | NCT05538130 | |
| NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor | Not yet recruiting | Phase 2 | 2026-08-21 | NCT07261241 | |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm, susceptibility to familial cutaneous melanoma | Recruiting | Phase 3 | 2026-08-18 | NCT06743126 | |
| Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies | Advanced Solid Malignancies | Recruiting | Phase 1 / Phase 2 | 2026-08-17 | NCT06028074 | |
| Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-08-14 | NCT06425926 | |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Adnexal Diseases, Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, biliary tract disorder, breast disorder, breast neoplasm, carcinoma, cholangiocarcinoma, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastrointestinal stromal tumor, glioma, gonadal disorder, hepatocellular carcinoma, liver disorder, malignant endocrine neoplasm, neoplasm, neuroepithelial neoplasm, ovarian cancer, ovarian disorder, primitive neuroectodermal tumor, skin disorder, thyroid gland undifferentiated (anaplastic) carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder | Recruiting | Phase 2 | 2026-07-27 | NCT05503797 | |
| Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urothelial carcinoma | Active, not recruiting | Phase 3 | 2026-07-22 | NCT05911295 | |
| VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] | Advanced Melanoma | Recruiting | Phase 3 | 2026-07-15 | NCT06264180 | |
| Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Disease Attributes, Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-07-14 | NCT05533697 | |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2026-04-01 | NCT04486352 | |
| Neuroblastoma Precision Trial | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Not stated | 2026-03-23 | NCT02868268 |